Navigation Links
Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
Date:12/11/2008

TUSTIN, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that Thomas A. Waltz, M.D., chairman of its Board of Directors, unexpectedly passed away on Wednesday. Dr. Waltz had been a director of Peregrine since 2004 and was chairman since 2005. At the time of his death, Dr. Waltz served on Peregrine's Audit Committee, Compensation Committee and Nominating Committee.

"The sudden loss of our business colleague and friend Tom Waltz brings sadness to the entire Peregrine family," said Steven W. King, president and CEO of Peregrine. "Our deepest sympathies go out to Tom's family and to all who knew him well. Tom's distinguished career as a top neurosurgeon and healthcare executive was matched by his generosity and spirit. His medical and healthcare expertise was of significant value to Peregrine and his talents, wisdom and guidance will be missed."

Dr. Waltz was a neurosurgeon and a senior consultant in Neurosurgery at the Scripps Clinic in La Jolla, California. He formerly was chairman and CEO of the Scripps Clinic and president of the Scripps Clinic Medical Group. Dr. Waltz also served on the Board of Genoptix Inc. and Premera Blue Cross of Washington and Alaska. He received his undergraduate degree from the University of Cincinnati, his M.D. from Vanderbilt University and his neurosurgical training at Baylor College of Medicine. Dr. Waltz also had training in Neurology at The National Hospital for Neurological Diseases and in Neuropathology at Oxford University, both in the U.K.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C vir
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
2. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
3. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
5. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
6. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
8. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
9. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
10. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., BOSTON, Nov. 25 Biotech firm Rep...nomic data from the 1918 pandemic through the pred... pandemic, today issued its latest biochemical ana...thality of the H1N1 ("Swine Flu") virus has droppe...,s current outbreak in the spring of 2009 to resti...
(Date:11/25/2009)... , ,, BOCA RATON, Fla., Nov. 25 /P... painful year. Not so for BodyLogicMD. The nation...hysicians specializing exclusively in medically su...mber of physicians in its network since Nove...progress to add more physician-owned centers, incl...
(Date:11/25/2009)..., BEIJING, Nov. 25 /PRNewswire-Asia/ -- Sinov...ovider of vaccines, announced today that it execut...ovac (Dalian) Vaccine,Technology Co., Ltd. (Sinova...and commercialize human-use vaccines. Sinovac will...ping and commercializing world-class vaccines; the...
(Date:11/25/2009)... DIEGO, Nov. 25 Ardea Bi...hat Barry D. Quart, Pharm.D., president and chief ...ay 21st Annual Health Care Conference. , ,Present...Annual Health Care Conference,Date: Tuesday, ...,Location: The New York Palace Hotel, New York, N...
Breaking Biology Technology:Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 4Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...nference Call Tomorrow (Tuesday) at 8:30 am EDT to... Valley Cottage, NEW YORK, September 10 XTL,Biop...E: XTL) today announced,the initiation of a Phase ... norepinephrine reuptake inhibitor (SNRI) - for th...ine is being developed for the treatment of diabet...
...ltern, a leading global research,organization, is ...,Chiltern,s Country Manager for the Czech Republic...e year award. The award ceremony was held in,Londo...om amongst his peers by a panel of judges who,revi...ccessful conclusion,of clinical trials. The judgin...
Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
Other Biology Technology:XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year 2
(Date:11/25/2009)...ientists at the California Institute of Technology...emotion-like behavior in the fruit fly, Drosophil...relevant to the relationship between the neurotran...ty disorder (ADHD), are described in the December ... brain contains only about 20,000 neurons and has...
(Date:11/25/2009)...BER 25, 2009 Soil is the linchpin of the environm...meet. Despite that, many students see soil as "jus... Soil science educators are challenged with the ta...e critical importance of soil in the environment. ...arth science teachers at University of Nebraska-Li...
(Date:11/24/2009)... Institute (LRI) today named 12 new grant recipien...cognize innovative work across a broad spectrum of...ivity, novelty, and potential to drive scientific ...he complex disease of systemic lupus. , The 2009...rchers across the nation and include interdiscipli...
Breaking Biology News(10 mins):Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4It's not just dirt! 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3PEAK Surgical Announces Results of First PRECISE Studies at American College of Surgeons Clinical Congress 5492 1PEAK Surgical Announces Results of First PRECISE Studies at American College of Surgeons Clinical Congress 5492 2PEAK Surgical Announces Results of First PRECISE Studies at American College of Surgeons Clinical Congress 5492 3Inc Magazine Unveils 28th Annual List of Americas Fastest Growing Private Companies the Inc 500 59482 1Inc Magazine Unveils 28th Annual List of Americas Fastest Growing Private Companies the Inc 500 59482 2IDEXX Laboratories to Release 2009 Third Quarter Financial Results 14472 1
... Society for Microbiology (ASM) Eli Lilly and Comp... Newman, Wilson Professor of Biology and Geobiolog...rd recognizes fundamental research of unusual meri...n the threshold of his or her career. , Dr. Newma...ed the field of geomicrobiology. Her seminal resea...
... Society for Microbiology (ASM) William A. Hinton ...ro Casadevall, Chair, Department of Microbiology a..., Yeshiva University, New York. This award recogni... research training of underrepresented minorities ...emplary training and mentoring to a significant nu...
...ociety for Microbiology (ASM) Merck Irving S. Siga...rrell, Assistant Professor, Department of Microbio...ersity of the Health Sciences (USUHS), Bethesda, M... the Merck Irving S. Sigal Memorial Award is prese...ental in the early discovery of therapies to treat...
Other Biology News:American Society for Microbiology honors Dianne K. Newman 2American Society for Microbiology honors Arturo Casadevall 2
Goat Anti-Mouse IGSF4 Polyclonal Antibody, Unconjugated from R&D Systems
Rat Anti-Mouse Activin RIB / ALK-4 Monoclonal Antibody, Unconjugated, Clone 207304 from R&D Systems
Normal Human Serum from 3H Biomedical AB
...s for SYBR Green, TaqMan, LNA spiked TaqMan, Methy...ghly specific primers are designed by avoiding cro...BLAST search results. Primer efficiency is enhance...fied by connecting to the Mfold server. Beacon Des...
Biology Products: